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Genetic reduction 
of the extracellular matrix protein 
versican attenuates inflammatory 
cell infiltration and improves 
contractile function in dystrophic 
mdx diaphragm muscles
natasha L. McRae1, Alex B. Addinsall1,2*, Kirsten f. Howlett3, Bryony McNeill1, 
Daniel R. Mcculloch1 & nicole Stupka1,4,5*
There is a persistent, aberrant accumulation of V0/V1 versican in skeletal muscles from patients 
with Duchenne muscular dystrophy and in diaphragm muscles from mdx mice. Versican is a 
provisional matrix protein implicated in fibrosis and inflammation in various disease states, yet its 
role in the pathogenesis of muscular dystrophy is not known. Here, female mdx and male hdf mice 
(haploinsufficient for the versican allele) were bred. In the resulting F1 mdx-hdf male pups, V0/V1 
versican expression in diaphragm muscles was decreased by 50% compared to mdx littermates at 
20–26 weeks of age. In mdx-hdf mice, spontaneous physical activity increased by 17% and there was 
a concomitant decrease in total energy expenditure and whole-body glucose oxidation. Versican 
reduction improved the ex vivo strength and endurance of diaphragm muscle strips. these changes 
in diaphragm contractile properties in mdx-hdf mice were associated with decreased monocyte 
and macrophage infiltration and a reduction in the proportion of fibres expressing the slow type 
I myosin heavy chain isoform. Given the high metabolic cost of inflammation in dystrophy, an 
attenuated inflammatory response may contribute to the effects of versican reduction on whole-body 
metabolism. Altogether, versican reduction ameliorates the dystrophic pathology of mdx-hdf mice as 
evidenced by improved diaphragm contractile function and increased physical activity.
Abbreviations
½ RT  ½ Relaxation time
ADAMTS  A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs
CK  Creatine kinase
CS  Chondroitin sulphate
DAPC  Dystropin-associated protein complex
ECM  Extracellular matrix
GAG  Glycosaminoglycan
Lo  Optimal length
MCP-1  Macrophage chemoattractant protein-1
open
1Centre for Molecular and Medical Research, School of Medicine, Deakin University, Waurn Ponds, VIC 3216, 
Australia. 2Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. 3Institute of 
Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC 3216, 
Australia. 4Present address: Australian Institute for Musculoskeletal Science (AIMSS), University of Melbourne and 
Western Health, St Albans, VIC, Australia. 5Present address: Department of Medicine -Western Health, Melbourne 




Scientific RepoRtS |        (2020) 10:11080  | https://doi.org/10.1038/s41598-020-67464-x
www.nature.com/scientificreports/
RER  Respiratory exchange rate
sPo  Specific force
sPt  Specific twitch force
TGFβ  Tumor growth factor beta
TPT  Time to peak tension
Duchenne Muscular Dystrophy (DMD) is an X-linked, paediatric disease arising from a mutation in the dys-
trophin (DMD) gene leading to the loss of expression of dystrophin and the dystrophin associated protein 
complex (DAPC)1, which renders muscles highly vulnerable to degeneration. Increasing fibrosis and excessive 
inflammation compromise muscle repair leading to muscle wasting and expansion of the extracellular  matrix2,3. 
Skeletal, respiratory and cardiac muscles are affected in DMD, leading to a loss of ambulation, poor respiratory 
and cardiac function, and a greatly reduced life expectancy due to cardiorespiratory  failure4–6. Endomysial fibrosis 
is a hallmark of DMD pathology and an active driver of disease progression as it precedes overt degeneration. 
Expansion of the interstitial matrix is observed in skeletal muscle biopsies from patients with DMD as young 
as 2.5 weeks of  age2,7.
The carefully regulated synthesis and remodelling of the extracellular matrix (ECM) is necessary for effective 
muscle regeneration. This initially requires the synthesis of a hydrated provisional matrix enriched in versican, 
hyaluronan and fibronectin, which modulates cell behaviour relevant to inflammation and  regeneration8,9. This 
provisional matrix then needs to be carefully remodelled and replaced with a collagen rich, mature  matrix8. Failed 
regeneration is characterized by the excessive and persistent accumulation of collagen, proteoglycans and vari-
ous provisional matrix proteins. Indeed, fibrosis in dystrophic muscles is comprised of mature and provisional 
matrix proteins, such as the fibrillar collagen isoforms I and  III10,11,  fibronectin12,13, and the chondroitin sulphate 
(CS) proteoglycans decorin, biglycan and the V0/V1 isoforms of  versican14–16. Excess versican is associated with 
fibrosis and pathology in lung, liver and cardiovascular  disease17,18, its role in the pathogenesis of neuromuscular 
disease is not known. However, versican expression is increased in skeletal muscle biopsies from patients with 
DMD compared to healthy controls, as assessed by  immunohistochemistry15,19 and microarray gene expression 
 analysis20. Furthermore, in skeletal muscle biopsies from patients with DMD there is far greater deposition of 
CS/dermatan sulphate side chains than in control  biopsies21. Versican is likely to be a significant source of these 
CS side chains, because of all the CS proteoglycans upregulated in dystrophic muscles, V0/V1 versican is the 
most highly  glycosylated21.
In skeletal muscle, it is the V0 and V1 isoforms of versican which are most highly  expressed22. V0/V1 versi-
can is composed of N- and C-terminal globular domains and up to two binding regions for glycosaminoglycan 
(GAG) CS side chains (GAGα and GAGβ)23. The V0 versican variant contains the GAGα and GAGβ domains 
and is therefore more highly glycosylated than the V1 variant, which only contains the GAGβ  domain24,25. V0/V1 
versican is proteolytically processed by ADAMTS versicanases. This produces the bioactive versikine fragment, 
which depending on biological context can stimulate  apoptosis26,  inflammation27, or modulate mitotic spindle 
organisation in proliferating  cells28.
There is emerging evidence that V0/V1 versican synthesis and remodelling is closely associated with cel-
lular processes necessary for effective regenerative myogenesis and driving the pathogenesis of DMD. This 
includes satellite cell  proliferation29, myoblast fusion and myofibre  formation22, and modulation of inflammatory 
 responses30–32. By binding cytokines, chemokines and growth factors, such as TGFβ and monocyte chemoat-
tractant protein-1 (MCP-1)30, versican CS side chains have important effects on cell signalling and  behaviour23. 
TGFβ is highly upregulated in dystrophic muscles, where it is implicated in impaired regenerative myogenesis 
and  fibrosis33,34. The pro-fibrotic effects of TGFβ1 include further upregulation of versican  synthesis35. MCP-1 
stimulates monocytes and macrophage infiltration across the vasculature into  tissue30, and is upregulated in 
dystrophic  muscles36,37. Versican also has direct effects on macrophage and monocyte adhesion and  migration38, 
and on the monocyte to macrophage  transition39. Infiltrating macrophages not only synthesise versican, but 
are also involved in its remodelling through the secretion of ADAMTS  versicanases40. Fibroblasts are also a 
source of versican and ADAMTS  versicanases41. If versican is in excess, then the differentiation of fibroblasts 
into myofibroblasts is  stimulated42,43, these are characterized by their high level of collagen  synthesis44. In mdx 
mice, diaphragm muscles model DMD pathology well, arguably better than hindlimb muscles, presenting with 
decreased muscle strength and endurance, excessive inflammation, insufficient regeneration, and progressively 
increasing  fibrosis45–48. Importantly, V0/V1 versican is highly  upregulated14.
Metabolic dysfunction is another important sequalae of dystrophin deficiency in patients with DMD and 
in mdx  mice49. It is characterized by impaired mitochondrial function and reduced ATP  production50, as well 
alterations in whole-body  metabolism51. Physical activity is decreased and energy expenditure is increased in mdx 
mice when compared to wild type  mice51. Unlike in mdx mice, resting energy expenditure is reduced in patients 
with DMD compared to normal age matched control  values52,53. Nonetheless, in patients with DMD there is a 
strong association with resting energy expenditure and vital capacity, with increasing energy requirements as 
respiratory function declines in the later stages of the  disease52.
Here, a genetic approach was used to test the hypothesis that versican reduction would ameliorate the pathol-
ogy of mdx mice and improve the function of dystrophic diaphragm muscles. Thus, female mdx mice were bred 
with male heart defect mice (hdf) mice, which are haploinsufficient for the versican allele, to generate F1 mdx 
male pups. At 20–26 weeks of age, male F1 mdx-hdf mice with a single functional allele and a concomitant 
whole-body reduction in versican protein expression and mdx control littermates with two functional versican 
alleles were used to investigate the effects of versican reduction on physical activity, whole-body metabolism, 
and diaphragm muscle contractile properties and morphology.
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Figure 1.  V0/V1 versican and versikine localization and expression in diaphragm muscles from mdx and 
mdx-hdf mice. Versican or versikine immunoreactivity in red; nuclei were counterstained with DAPI (blue). 
(A, B) Representative versican staining in diaphragm cross-sections from mdx and mdx-hdf mice. (C) Versican 
immunoreactivity was reduced in diaphragm muscles from mdx-hdf mice compared to mdx littermates 
(*p = 0.0004). (D–E) Representative versikine staining in diaphragm cross-sections from mdx and mdx-hdf 
mice. (F) Versikine immunoreactivity did not differ between mdx and mdx-hdf diaphragm muscles (p = 0.192). 
(G) V0/V1 Vcan mRNA transcripts (*p = 0.005) and (H) Has2 mRNA transcript (*p < 0.05) were reduced in 
diaphragm muscles from mdx-hdf mice versus mdx littermates. N = 11–13 mdx and N = 11–12 mdx-hdf mice 
for versican and versikine immunoreactivity. N = 12 mdx and N = 11 mdx-hdf mice for gene expression. Scale 
bar = 100 µm.
Figure 2.  V0/V1 versican remodelling is associated with areas of regeneration and inflammation in mdx 
diaphragm muscles. Serial cross-sections were immunoreacted with primary antibodies against desmin (green) 
or CD68 (green) and versikine (red); nuclei were counterstained with DAPI (blue). Phase images were captured 
for orientation. (A–D) Desmin positive myoblasts and myotubes or (E–H) CD68 positive monocytes and 
macrophages were localized to regions of versikine immunoreactivity in the endomysium. Scale bar = 100 µm.
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Results
full length versican expression is decreased in diaphragm muscles from mdx-hdf mice. In 
diaphragm muscle cross-sections from mdx and mdx-hdf mice, versican immunoreactivity was localised to the 
endomysium (Fig. 1A, B). Immunoreactivity of the cleaved bioactive versikine fragment was also localised to 
the endomysium (Fig.  1D, E), as well as to regions of mononuclear infiltrate (Figs.  2A, D, 3A, D), which is 
comprised of inflammatory cells, myoblasts and fibroblasts. When the percentage of versican immunoreactiv-
ity in diaphragm cross-sections was quantified, versican protein expression was reduced by approximately 50% 
in diaphragm muscles from mdx-hdf mice when compared to mdx littermates (p = 0.0004; Fig. 1C), which was 
supported by a similar decrease in V0/V1 Vcan mRNA transcript abundance (p = 0.005; Fig. 1G). This confirms 
successful haploinsufficiency of versican in dystrophic diaphragm muscles using the hdf mouse model. In con-
trast to full length V0/V1 versican, versikine immunoreactivity did not significantly differ between diaphragm 
muscles from mdx and mdx-hdf mice (Fig. 1F). This was not unexpected, as ADAMTS-generated versikine is 
Figure 3.  Co-localization of versikine with monocytes and macrophages in mdx diaphragm muscles. 
Diaphragm cross-sections were immunoreacted with primary antibodies against (A) versikine (red) and (B) 
F4/80 (green), and nuclei were counterstained with DAP1 to show tissue morphology. (C) The merged image 
shows the presence of F4/80 positive macrophages in regions of versican remodelling (arrows). Diaphragm 
cross sections were also immunoreacted with primary antibodies against (D) CD68 (red) and (E) F4/80 (green). 
(F) The colocalization of CD68 with F4/80 (arrowheads) demonstrates the utility of CD68 as an inflammatory 
cell marker. (G) Representative negative control sections reacted with the goat anti-rabbit and goat anti-rat 
secondary antibodies. Scale bar = 50 µm.
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not an end product and is further  degraded22. Within the provisional matrix, there is a close association between 
versican and  hyaluronan9. Interestingly, the mRNA transcript abundance of Has2, the predominant hyaluronan 
synthase isoform in skeletal  muscle54, was also decreased in diaphragm muscles from mdx-hdf mice compared 
to mdx littermates (p = 0.0329; Fig. 1H).  
To demonstrate the association between versican remodelling and regenerative myogenesis or inflammation, 
serial diaphragm muscle cross-sections were reacted with antibodies against versikine and desmin which is highly 
expressed in myoblasts and newly regenerated  myotubes55 or the monocytes and macrophage marker  CD6856,57. 
Versikine was highly expressed in regions of mononuclear infiltrate (Fig. 2A, E, white outline), which comprised 
desmin positive muscle cells (Fig. 2C) and CD68 positive inflammatory cells (Fig. 2G).
To confirm the association between versican remodelling and inflammation, diaphragm cross-sections were 
reacted with primary antibodies, raised in different species against versikine (Fig. 3A) and the pan-macrophage 
marker F4/80 (Fig. 3B). In concordance with the serial section findings presented in Fig. 2E–H, F4/80 posi-
tive macrophages were co-localized with regions of endomysial versikine staining (Fig. 3C). To confirm the 
suitability of CD68 as a macrophage marker, diaphragm cross-sections were reacted with the CD68 antibody 
raised in rabbits (Fig. 3D) and the pan-macrophage marker F4/80 antibody raised in rats (Fig. 3E), as expected 
co-localization between these two markers was observed (Fig. 3F).
Effects of versican reduction on the body composition of mdx mice. Despite the association 
between versican synthesis, myogenesis and muscle  growth29, the genetic reduction of versican did not affect 
body weight or composition. Lean mass and fat mass expressed in grams or as a percentage of body weight did 
not significantly differ between mdx and mdx-hdf mice (Table 1).
Increased spontaneous physical activity in mdx-hdf mice. Serum creatine kinase (CK) activity, a 
marker of muscle damage, was not significantly affected by the genetic reduction of versican (Fig. 4A), despite 
the mdx-hdf mice being more physically active than their mdx littermates (p = 0.024; Fig. 4B). This increase in 
spontaneous physical activity in mdx-hdf mice is interesting given that physical activity and exercise capacity are 
reduced in mdx mice compared to wild type  mice51.
The genetic reduction of versican has favourable effects on whole-body energy balance and 
metabolism in mdx mice. Corresponding to increased nocturnal activity, in mdx-hdf mice and mdx lit-
Table 1.  Body weight, fat mass and lean mass as determined by ECHO-MRI. Data are mean ± SEM. N = 14 
mdx and N = 16 mdx-hdf mice.
mdx mdx-hdf P value
Body weight (g) 32.24 ± 0.50 32.46 ± 0.70 0.80
Fat (g) 1.44 ± 0.20 1.78 ± 0.15 0.18
Fat (%) 4.41 ± 0.57 5.49 ± 0.44 0.14
Lean mass (g) 29.77 ± 0.41 30.22 ± 0.66 0.58
Lean mass (%) 92.40 ± 0.52 93.10 ± 0.68 0.43
Figure 4.  The genetic reduction of versican was associated with increased spontaneous physical activity. (A) 
Serum CK activity did not significantly differ between mdx and mdx-hdf mice (p = 0.598). (B) During 24 h in 
metabolic cages, mdx-hdf mice were more active than their mdx littermates as indicated by an increase in total 
movement (*p = 0.024). N = 8 mdx and N = 9 mdx-hdf for serum CK activity, and N = 12 mdx and N = 15 mdx-
hdf mice for spontaneous physical activity analysis.
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termates, oxygen consumption  (VO2 12 h sum), energy expenditure (12 h sum), glucose oxidation (12 h sum), 
and the respiratory exchange ratio (RER), but not fat oxidation (12 h sum), were higher during the 12 h dark 
than the 12 h light period (p < 0.05; Fig. 5A–C, E). Average 12 h values for oxygen consumption  (VO2), energy 
expenditure, glucose and fat oxidation were also calculated, and similar diurnal trends were observed (data not 
shown).
The genetic reduction of versican may have favourable effects on whole-body metabolism. When summed 
over the 12 h dark or light period, total oxygen consumption  (VO2 12 h sum) (p = 0.006; Fig. 5A), exergy expendi-
ture (p = 0.033; Fig. 5B), glucose oxidation (p < 0.001; Fig. 5C), but not fat oxidation (Fig. 5D), were lower in 
mdx-hdf mice compared to mdx littermates. In concordance with the reduction in glucose oxidation, the 12 h 
Figure 5.  The genetic reduction of versican improved whole-body energy balance in mdx mice. (A) * In all 
mice, oxygen consumption  (VO2 12 h sum) was higher during the 12 h dark period versus the 12 h light period. 
† Irrespective of the light or dark period,  VO2 sum was lower in mdx-hdf mice compared to mdx littermates. 
(B) * Energy expenditure (12 h sum) was higher during the 12 h dark period and † lower in mdx-hdf mice. (C) 
* Glucose oxidation (sum) was higher during the 12 h dark period and † lower in mdx-hdf mice. (D) There was 
no significant difference in lipid oxidation (12 h sum) between the dark and light period nor between mdx and 
mdx-hdf mice. (E) * RER was higher during the 12 h dark period and † lower in mdx-hdf mice. † P < 0.05; main 
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average RER values were lower in mdx-hdf mice compared to mdx littermates (p = 0.013; Fig. 5E), irrespective 
of the light or dark period.
Stroke volume is maintained despite increased heart mass and left ventricular dilatation in 
mdx-hdf mice. Similar to patients with DMD, older mdx mice develop a dilated cardiac myopathy and 
myocardial fibrosis which can be observed from 42 weeks of  age58. Hdf mice were first used to establish that ver-
sican is essential for the correct embryonic development of the heart, including formation of the right ventricle 
and the intraventricular  septum59–61. Given that versican is also associated with fibrosis in various pathological 
 contexts9, echocardiography was used to assess the morphological and functional effects of versican reduction 
on the mdx heart. At 25 weeks of age, there was no histological evidence of fibrosis in hearts from either mdx 
or mdx-hdf mice (Fig. S1). However, hearts from mdx-hdf mice were heavier than those from mdx littermates 
(p = 0.032; Table  2), even when normalized to body weight (p = 0.020; Table  2). Based on echocardiography 
measures, the thickness of the intraventricular septum (IVS) and the left ventricular posterior wall (LVPW) 
dimensions did not significantly differ between mdx and mdx-hdf mice in either systole or diastole. During 
systole, but not diastole, the left ventricular internal diameter (LVID) was greater in mdx-hdf mice compared to 
mdx littermates (p = 0.03). This suggests development of a dilated cardiac myopathy with systolic dysfunction. In 
concordance with this, fractional shortening (FS; p = 0.02) and the ejection fraction (EF; p = 0.03) were decreased 
in hearts from mdx-hdf mice. Nonetheless, stroke volume was maintained in mdx-hdf mice, such that it did not 
differ from mdx littermates.
The genetic reduction of versican improved the ex-vivo strength and endurance of dystrophic 
diaphragm muscles. In response to a 1 Hz stimulation, a modest increased in time to peak tension (TPT) 
was observed in diaphragm muscles from mdx-hdf mice (p = 0.03), whilst normalized twitch force  (sPt) and half 
relaxation time (½RT) were not significantly increased in diaphragm muscle strips from mdx-hdf mice versus 
mdx littermates (Table 3).
With increasing stimulation frequency, the genetic reduction of versican increased the normalized force 
output  (sPo) of diaphragm muscles, as indicated by an upward shift of the force frequency curve (p < 0.001; 
Fig. 6A). To assess fatigability and force recovery, diaphragm muscle strips were subjected to 4 min of intermit-
tent, 60 Hz stimulation with force recovery assessed at 2, 5 and 10 min post fatigue. During the 4 min fatigue 
Table 2.  Echocardiography findings from mdx and mdx-hdf mice at 25 weeks of age. Data are mean ± SEM. 
IVS d/s = interventricular septal dimension (diastole/systole); LVID d/s = left ventricle internal diameter 
(diastole/systole); LVPWD d/s = left ventricular posterior wall dimensions (diastole/systole); SV = stroke 
volume; EF = ejection fraction; FS = fractional shortening; LV = left ventricle. N = 13 mdx and N = 16 mdx-hdf 
for heart weight data. N = 8 mdx and N = 12 mdx-hdf for echocardiography.
Units mdx mdx-hdf P value
Heart weight mg 142.6 ± 3.0 153.0 ± 3.4 0.03*
Heart:Body weight ratio mg:g 4.4 ± 0.1 4.7 ± 0.1 0.02*
IVSd (MM) cm 0.099 ± 0.004 0.105 ± 0.002 0.15
IVSs (MM) cm 0.185 ± 0.006 0.178 ± 0.010 0.58
LVIDd (MM) cm 0.284 ± 0.009 0.309 ± 0.020 0.35
LVIDs (MM) cm 0.122 ± 0.011 0.173 ± 0.015 0.03*
LVPWDd (MM) cm 0.106 ± 0.005 0.106 ± 0.005 0.95
LVPWDs (MM) cm 0.159 ± 0.006 0.152 ± 0.007 0.43
SV (MM-cubed ml 0.021 ± 0.002 0.027 ± 0.005 0.36
EF (MM-cubed) % 90.5 ± 2.5 80.7 ± 3.0 0.03*
FS (MM-cubed % 56.8 ± 4.0 44.1 ± 3.2 0.02*
LV Mass (cubed) g 0.678 ± 0.004 0.697 ± 0.011 0.20
Table 3.  Ex-vivo twitch (1 Hz) contractile properties of diaphragm muscles from mdx and mdx-hdf at 
21 weeks of age. Data are mean ± SEM. sPt = specific twitch force; TPT = time to peak tension; ½ RT = half 
relaxation time. N = 11 mdx mice and N = 15 mdx-hdf mice.
Units mdx mdx-hdf P value
Diaphragm strip mass mg 8.18 ± 0.57 7.95 ± 0.55 0.77
sPt kN/m2 14.45 ± 1.80 17.97 ± 1.64 0.17
TPT s 0.2301 ± 0.0005 0.2314 ± 0.0004 0.03*
½ RT s 0.031 ± 0.002 0.035 ± 0.002 0.11
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protocol, diaphragm muscles from mdx-hdf mice fatigued less compared to their mdx littermates (p < 0.001), 
and force recovery was also improved (p < 0.001; Fig. 6B).
Muscle morphology and gene markers of myogenesis and apoptosis in dystrophic diaphragm 
muscles in response to the genetic reduction of versican. Characteristic of the pathology of dys-
trophic diaphragm muscles, myofibres were variable in size and greater than one third were centrally nucleated, 
indicative of damage and repair. In concordance with V0/V1 versican and verskine immunoreactivity results 
(Figs. 1, 2), endomysial fibrosis and mononuclear infiltrate were also readily evident in H&E strained cross-
sections (Fig. 7A, B). With the exception that diaphragm muscles from mdx-hdf mice had significantly fewer 
very small myofibres < 9.99 µm in size (p = 0.031; Fig. 7C), the genetic reduction of versican had negligible effects 
on muscle fibre size, as assessed using minimal feret diameter. With regards to markers of muscle regeneration, 
the genetic reduction of versican did not significantly alter the proportion of centrally nucleated fibres (Fig. 7D) 
nor did it alter the mRNA transcript abundance of Myogenin (Fig. 7E). Caspase-3 gene expression tended to be 
lower in diaphragm muscles from mdx-hdf mice compared to mdx littermates (p = 0.055; Fig. 7F), whether this 
is in fact associated with decreased apoptosis and degeneration requires further investigation, as this too could 
contribute to the positive effects of versican reduction on mdx diaphragm muscle function (Fig. 6).
Inflammation and fibrosis in dystrophic diaphragm muscles in response to the genetic reduc-
tion of versican. The genetic reduction of versican attenuated inflammation in dystrophic diaphragm mus-
cles, as indicated by an approximately 50% decrease in the number of infiltrating CD68 positive macrophages 
and monocytes in diaphragm muscle cross-sections from mdx-hdf mice versus mdx littermates (p < 0.001; 
Fig. 8A–C). This is in concordance with published observations, that excess V0/V1 versican stimulates mac-
rophage infiltration in various pathological  contexts62,63. Furthermore, the mRNA transcript abundance of the 
inflammatory markers Mcp-1 and Tgfβ1 mRNA tended to be decreased in diaphragm muscles from mdx-hdf 
mice (p = 0.085 and p = 0.096, respectively; Fig. 8D–E).
By binding to  proteoglycans64 and  collagen65, which are all upregulated in dystrophic  muscles3,66, WGA 
can be used to visualize and quantify  fibrosis67. Despite the reduction in versican expression, the proportion 
Figure 6.  The genetic reduction of versican increased the ex vivo strength and endurance of isolated costal 
diaphragm muscle strips. (A) Haploinsufficiency of versican increased the specific force output  (sPo) of 
diaphragm muscle strips, as indicated by the upward shift in the force frequency curve (*p < 0.001; main effect 
genotype; 2-way GLM-ANOVA). (B) During 4 min of intermittent, 60 Hz stimulation, the relative fatigability 
of diaphragm muscles from mdx-hdf mice was reduced versus mdx littermates (*p < 0.001; main effect 
genotype; 2-way GLM ANOVA), and following 2, 5 and 10 min of rest relative force recovery was also improved 
(*p < 0.001; main effect genotype; 2-way GLM ANOVA). N = 11 mdx and N = 14 mdx-hdf mice.
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of muscle cross-section stained with WGA did not differ between diaphragm muscle cross-sections from mdx 
and mdx-hdf mice (Fig. 9C). To assess whether targeting the provisional matrix would affect the deposition of 
a collagen rich mature  matrix8, hydroxyproline content, a measure of tissue collagen  content68, was determined 
in diaphragm muscle lysates from mdx-hdf mice and mdx littermates. In concordance with the WGA data, the 
genetic reduction of versican did not significantly alter the collagen content of dystrophic diaphragm muscles 
(Fig. 9D). With the exception of Col3a1 (p = 0.033), Col1a1 (p = 0.082), Col4a1 (p = 0.390), Decorin (p = 0.083), 
Biglycan (p = 0.298), and Adamts-5 (p = 0.076) gene expression was not significantly different in mdx-hdf mice 
Figure 7.  Effects of versican reduction diaphragm muscle morphology and gene markers of myogenesis and 
apoptosis. (A–B) Representative H&E stained sections of mdx and mdx-hdf diaphragm cross-sections. (C) 
Diaphragm muscles from mdx-hdf had fewer very small fibres > 9.99 µm in diameter (*p = 0.031; t test). (D) 
The percentage of centrally nucleated fibres did not significantly differ between muscles from mdx-hdf mice 
versus mdx littermates. (E) The mRNA transcript abundance of Myogenin did not significantly differ between 
diaphragm muscles from mdx-hdf mice and mdx littermates (p = 0.2575). (F) The mRNA transcript abundance 
of Caspase 3 tended to be lower in diaphragm muscles from mdx-hdf mice (p = 0.055). N = 11 mdx and N = 11 
mdx-hdf mice for muscle histology and morphology. N = 12 mdx and N = 12 mdx-hdf mice for gene expression 
analysis. Scale bar = 100 µm. 
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compared to mdx littermates (Fig. 9E–K). Thus, in dystrophic diaphragm muscles the genetic reduction of 
versican had very modest effects on the transcription of ECM associated genes which were not supported by 
histological and biochemical markers of fibrosis.
The effects of versican reduction on fibre type in dystrophic diaphragm muscles. The predomi-
nant myosin heavy chain (MyHC) isoform in diaphragm muscles from adult mdx mice is the fast oxidative 
MyHC type IIa isoform, with 55% fibres expressing this isoform whilst 10% of fibres express the slow MyHC type 
 I69. This is in concordance with our observations of a greater prevalence of MyHC type IIa than MyHC type I 
fibres in dystrophic diaphragm muscle cross-sections (Fig. 8A–D). The number of MyHC type IIa fibres per  mm2 
of diaphragm cross-section did not significantly differ between mdx and mdx-hdf mice (p = 0.4516; Fig. 10E). 
However, the number of MyHC type I per  mm2 of diaphragm cross-section was ~ 30% lower in mdx-hdf mice 
compared to mdx littermates (*p = 0.0215; Fig. 10F). This reduction in the proportion of MyHC type I fibres, 
highlights the complex biological effects of versican in dystrophic muscles and may have have implications for 
contractile function.
Discussion
V0/V1 versican is highly upregulated in muscle biopsies from patients with  DMD15,19 and in dystrophic dia-
phragm muscles from mdx  mice14. Here, we present initial evidence that aberrant versican synthesis and remod-
elling may contribute to skeletal muscle dysfunction and degeneration in dystrophy. Specifically, we confirm the 
higher expression levels of versican in diaphragm muscles from mdx mice and show that the bioactive versikine 
fragment is co-localized with macrophages and monocytes (as identified by their CD68 and F4/80 immunore-
activity), as well as desmin positive myoblasts and newly regenerative myofibres. This highlights the association 
between versican remodelling, inflammation and myogenesis in dystrophic diaphragm muscles.
Figure 8.  Versican reduction decreased inflammation in dystrophic diaphragm muscles. (A–B) Representative 
CD68 staining in diaphragm cross-sections from mdx and mdx-hdf mice with CD68 positive macrophages 
(brownish-red; AEC) and nuclei (blue; hematoxylin). (C) The number of infiltrating CD68 positive monocytes 
or macrophages per  mm2 tissue was lower in diaphragm cross-sections from mdx-hdf mice compared to mdx 
littermates (*p < 0.0001). (D–E) Mcp-1 and Tgfβ1 mRNA transcript abundance was not significantly decreased 
in diaphragm muscles from mdx-hdf mice versus mdx littermates (p = 0.085 and p = 0.096; respectively). N = 10 
mdx and N = 15 mdx-hdf mice for assessment of macrophage infiltration. N = 12 mdx and N = 12 mdx-hdf mice 
for gene expression analysis. Scale bar = 100 µm. 
11
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11080  | https://doi.org/10.1038/s41598-020-67464-x
www.nature.com/scientificreports/
Importantly, when V0/V1 versican gene and protein expression was reduced by approximately 50% in dia-
phragm muscles from mdx mice, ex vivo strength and endurance was improved, and inflammation (specifically, 
monocyte and macrophage infiltration) was attenuated. These improvements in diaphragm muscle contractile 
function and pathology were associated with an increase in spontaneous physical activity in mdx-hdf mice. 
Despite this increase in physical activity, there was no associated increase in muscle damage, as determined by 
serum CK activity and morphometric analysis of diaphragm muscle cross-sections, in mdx-hdf mice. Further-
more, the genetic reduction of versican had positive effects on whole-body energy balance and metabolism, as 
indicated by the decrease in whole-body oxygen consumption  (VO2), energy expenditure and glucose oxidation. 
This is an important observation as mdx mice are less active and have a higher energy expenditure than control, 
wild type C57/BL10  mice51. This high energy demand of dystrophy is also observed in young steroid-naive boys 
with DMD and manifests itself as compromised growth, height specifically, from a very early  age70. Altogether, 
our findings demonstrate the potential of targeting dysregulated versican synthesis to ameliorate the pathology 
of dystrophy.
This association between versican and inflammation has been reported in other disease contexts, where 
versican is thought to generate a matrix which promotes leukocyte migration and  adhesion41,71. Monocytes and 
macrophages can  synthesise72 and remodel V1/V0  versican73,74. In other biological contexts, a higher level of 
versican expression is observed in pro-inflammatory M1 compared to anti-inflammatory M2  macrophages72. 
This is interesting as in mdx mice the balance between M1 and M2 macrophages influences regenerative myo-
genesis with an excess of M1 macrophages being detrimental to dystrophic  muscles75–77. Recently, Coles et al. 
proposed that the ECM may be a major source of pro-inflammatory molecules which potentiate the immune 
response and drive pathology in dystrophic muscles, and they highlight versican as one such matrix  protein19. 
Figure 9.  Versican reduction does not attenuate fibrosis in dystrophic diaphragm muscles. (A–B) 
Representative mdx and mdx-hdf diaphragm sections stained with WGA (red) as marker of fibrosis; nuclei 
(blue; DAP1). (C) Fibrosis, as quantified by the proportion (%) of muscle cross-section stained with WGA, did 
not differ between the diaphragm muscles from mdx and mdx-hdf mice (p = 0.251). (D) Collagen content, as 
assessed by the hydroxyproline assay, also did not significantly differ between diaphragm muscles from mdx 
and mdx-hdf mice (p = 0.820). (E–K) With the exception of Col3a1 (*p = 0.033), versican reduction did not 
significantly decrease the mRNA transcript abundance of representative ECM proteins; specifically Col1a1 
(p = 0.082), Col4a1 (p = 0.390), Decorin (p = 0.083), Biglycan (p = 0.298), and Adamts-5 (p = 0.076). N = 9 mdx 
and  N = 10 mdx-hdf mice assessment of fibrosis with WGA. N = 8 mdx and N = 10 mdx-hdf mice for the 
hydroxyproline assay. N = 12 mdx and N = 12 mdx-hdf mice for gene expression analysis. Scale bar = 200 µm. 
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This proposition is supported by our findings where the genetic reduction of versican decreased infiltration of 
CD68 positive macrophages and monocytes into diaphragm muscles from mdx-hdf mice compared to mdx lit-
termates. In follow-up studies, it would be interesting to investigate whether versican reduction affects not only 
inflammatory cell infiltration, but also macrophage phenotype and  polarization. Corroborating this phenotype 
of reduced inflammation is the trend towards decreased Mcp-1 and Tgfβ1 gene expression. We would argue that 
this reduction in inflammation in mdx-hdf mice may have contributed to the increase in physical activity and 
the improvement in fatigability of isolated diaphragm muscle strips. Indeed, when pharmacological strategies, 
such as glucocorticoid  treatment78, protein kinase C θ  inhibition79, or blockade of the Il-6  receptor80 were used 
to attenuate inflammation in mdx mice, treadmill running performance, specifically the time to exhaustion, 
was improved.
The genetic reduction of versican also improved the ex vivo force output of dystrophic diaphragm mus-
cles. Contributing factors may include decreased inflammatory cell  infiltration81. Monocytes and macrophages, 
Figure 10.  Effects of versican reduction on myosin heavy chain (MyHC) isoform expression in dystrophic 
diaphragm muscles. (A–D) Representative cross-sections of MyHC type IIa (green) and MyHC type I (blue) 
immunoreactivity. (E) The number of MyHC type IIa fibres per  mm2 of diaphragm cross-section did not 
significantly differ between mdx and mdx-hdf mice (p = 0.4516; t test). (F) The number of MyHC type I fibres 
per  mm2 of diaphragm cross-section was reduced in mdx-hdf mice (*p = 0.0215). N = 10–11 mdx and N = 10 
mdx-hdf mice. Scale bar = 100 µm.
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especially M1 macrophages, are a potent source of pro-inflammatory mediators such as tumour necrosis factor-α 
(TNFα). These exacerbate pathology and potentiate contractile dysfunction in dystrophic muscles. In mdx mice, 
the genetic deletion of TNFα improved the ventilatory function, including increased ex vivo strength  (sPo) of 
diaphragm muscle  strips82. Similar to our observations, this was associated with reduced expression of the MyHC 
type I isoform and no significant change in the MyHC type IIa  isoform82. Whether the decrease in monocyte and 
macrophage infiltration in diaphragm muscles from mdx-hdf mice was associated with a concurrent reduction 
in TNFα protein levels should be investigated in follow-up studies.
The reduction in the proportion of very small muscle fibres (< 9.99 μm in diameter) in diaphragm muscles 
from mdx-hdf mice may be another contributing factor to the increase in force producing capacity. The posi-
tive correlation between fibre size and strength is well  established83, and the force producing capacity of these 
very small fibres is likely to be quite limited. Whilst the mechanisms as to why versican reduction affected the 
proportion of these very small muscle fibre size remain to be elucidated. Fewer very small fibers may relate 
to changes in de novo fiber formation and regeneration, and perhaps improved regenerative myogenesis. The 
upregulation of V0/V1 versican in dystrophic diaphragm muscles may impair fibre growth during regenerative 
myogenesis. Indeed, in differentiating C2C12 myoblasts inadequate clearance of a versican-rich provisional 
matrix leads to impaired myoblast fusion and myotube  formation22. Similarly, excess CS chains in the pericellular 
and interstitial matrix reduce myoblast fusion and myofibre growth in vitro and in vivo84, as V0/V1 versican is 
highly glycosylated and the genetic reduction of versican should reduce CS abundance in dystrophic muscles. 
This proposition needs to be carefully interrogated in follow-up studies using immunohistochemical staining 
for the embryonic and neonatal MyHC isoforms, which are expressed following the initiation of regeneration 
at 1 to 3 days post-damage and during ongoing regeneration 1 to 3 weeks post injury, respectively. It would be 
important to assess not just the proportion of embryonic and neonatal MyHC isoform positive fibres, but also 
their respective fibres size (min feret diameter).
It is unlikely that the increase in the specific force output of diaphragm muscles from mdx-hdf mice was medi-
ated by a reduction of fibrosis. The genetic reduction of versican, had very modest effects on ECM gene markers. 
With the exception of Has2 and Col3a1, the mRNA transcript abundance of Adamts-5, Col1a1, Col4a1, and the 
proteoglycans Biglycan and Decorin did not differ between diaphragm muscles from mdx-hdf and mdx mice. The 
gene data are supported by histological and biochemical analyses of fibrosis using WGA and the hydroxyproline 
assay (as a measure of total collagen content). In designing this study, we had  hypothesized that versican reduc-
tion would attenuate fibrosis in diaphragm muscles from mdx mice given the potential bidirectional associa-
tion between versican and fibrosis in other pathological contexts. For example, liver fibrosis is associated with 
excess versican synthesis, and in cultured hepatic stellate cells versican knockdown inhibited the expression of 
fibrogenic genes including Tgfβ1 and Collagen 117. TGFβ is a major driver of fibrosis in dystrophic  muscles3,34. 
Versican can regulate TGFβ bioavailability and increase active signalling in other biological  contexts42, whether 
TGFβ signaling was altered by versican reduction in mdx-hdf mice remains to be determined and as this may 
contribute to the lack of effect of versican reduction on fibrosis.
The effects of versican reduction on whole-body metabolism and diaphragm muscle endurance were unex-
pected, and it is unlikely that decreased inflammation is the only underpinning mechanism. Worthy of further 
investigation are the potential interactions between a versican-rich extracellular matrix and mitochondrial func-
tion, as there is increasing recognition that carefully regulated ECM synthesis and remodeling is fundamen-
tal for metabolic  regulation85,86. In hepatocellular carcinoma cells and patients with hepatocellular carcinoma, 
increased V0 versican stimulated glucose uptake and aerobic  glycolysis87. In cultured vascular endothelial cells, 
excess versican induced mitochondrial dysfunction when transported by exosomes to vascular smooth muscle 
 cells88. Whilst, in cell culture models of axon growth, chondroitin sulphate proteoglycans, though not versican 
specifically, impaired mitochondrial respiration and decreased ATP synthesis through downstream deleterious 
effects on the mitochondrial membrane potential, mitochondrial biogenesis and  morphology89,90. In the con-
text of insulin resistance and diabetes, aberrant remodelling of the skeletal muscle extracellular matrix alters 
mechano-signal transduction, which, in turn, disrupts the expression of genes relevant to oxidative metabolism 
and mitochondrial  biogenesis91,92. The potential effects of versican reduction on mechano-signal transduction 
and mitochondrial function in dystrophic muscles warrant further investigation; especially, since defects in 
mitochondrial function and ATP synthesis have been well described in dystrophic  muscles50,93,94.
In conclusion, our findings demonstrate the biological significance of versican as a therapeutic target in 
muscular dystrophy and highlight the positive, yet complex effects of versican reduction in dystrophic mdx mice. 
Follow up investigations targeting versican in dystrophic skeletal and cardiac muscles are required to build on 
these findings and these investigations need to employ genetic or pharmacological strategies that bypass the 
effects of versican reduction on embryonic development.
Methods
Ethics approval and mouse husbandry. This study was approved by the Animal Ethics Committees 
at Deakin University (A79/2011 and G06/2015). Animal care and experimental procedures were conducted 
in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. 
Female mdx (C57BL/10ScSn-Dmdmdx/Arc) mice, obtained from the Animal Resource Centre (Canning Vale, 
WA, Australia), were bred with male hdf (heart defect) mice. The hdf mice were obtained from Hoffman-La 
Roche Pharmaceuticals and are haploinsufficient for the versican  allele59. The resulting F1 mdx and mdx-hdf 
male pups were confirmed through genotyping and demonstrated the expected Mendelian genetic ratios. All 
mice were maintained in grouped cages (2–5 mice per cage) on an alternating 12 h light/dark cycle, at 21 ± 2 °C 
temperature, and 40–70% relative humidity. Water was provided ad libitum and mice were fed with standard 
mouse chow. Experimental procedures were completed on mice at 20 to 26 weeks of age.
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Echocardiography. Mice were anesthetized by inhalation of 1.5% isoflurane. Echocardiography was per-
formed using a HD15 Purewave Ultrasound System (Phillips). All functional parameters were measured in 
M-mode during systole (s) and diastole (d), and included interventricular septal dimension (IVSd, IVSs), left 
ventricular internal diameter (LVIDd, LVIDs), left ventricular posterior wall dimensions (LVPWd, LVPWs). 
From these stroke volume (SV), ejection fraction (EF), and fractional shortening were calculated.
Whole-body energy balance and metabolism and body composition. All mice underwent indi-
rect calorimetry (Fusion Metabolic System; AccuScan Instruments). Mice were individually placed in metabolic 
cages and were acclimatized for 3 h prior to measurements being recorded for 24 h. Energy expenditure and sub-
strate oxidation rates were determined using the equations by  Ferrannini95. Spontaneous physical activity was 
also measured using infrared sensors within the metabolic cages (Animal Activity Meter: Opto-Varimex-Mini; 
Columbus Instruments). Immediately prior to muscle function testing, conscious mice were weighed and placed 
in a rodent MRI (Body Composition Analyzer ESF-005, EchoMR) to determine lean and fat mass.
ex vivo diaphragm muscle function testing. Mice were anesthetized with medetomidine (0.5 mg/kg), 
midazolam (5 mg/kg) and fentanyl (0.05 mg/kg), administered via an IP injection in approximately 1 ml sterile 
saline, until unresponsive to tactile stimuli. Blood was collected by cardiac puncture for analysis of serum cre-
atine kinase (CK) activity. A diaphragm muscle strip (~ 5 mm wide) was excised from the linear muscle fibers in 
the left costal region of the diaphragm and prepared for contractile function testing, as previously  described96. 
Briefly, braided surgical silk (6/0) was tied to the central tendon and rib, and then the diaphragm muscle strip 
was transferred to an organ bath filled with Krebs Ringer solution (137 mM NaCl, 24 mM  NaHCO3, 11 mM 
D-glucose, 5 mM KCl, 2 mM  CaCl2, 1 mM  NaH2PO4H2O, 1 mM  MgSO4, 0.025 mM d-tubocurarine chloride; 
Sigma Aldrich), bubbled with Carbogen (5%  CO2 in  O2; BOC Gases) and maintained at 25 °C96. The central 
tendon was tied to an immobile pin, while the rib was attached to the lever arm of a dual mode force transducer 
(300-CLR; Aurora Scientific). Diaphragm muscle strips were stimulated via two platinum electrodes that flanked 
the length of the  muscle97. All stimulation parameters and contractile responses were controlled and measured 
using Dynamic Muscle Control Software (DMC v5.415), with an on-board controller interfaced with the trans-
ducer control/feedback hardware (Aurora Scientific) 97. Following determination of optimal length  (Lo), the 
maximal force producing capacity for the diaphragm muscle was determined from a force frequency curve rang-
ing from 1 to 120 Hz, with 2 min rest in between each stimulation. Fatigability and force recovery were assessed 
following 4 min of rest. Specifically, the diaphragm was stimulated at 60 Hz every 5 s for 4 min and then again 
at 2, 5 and 10 min post fatigue testing.
Following completion of function testing, the diaphragm muscle strips were trimmed of central tendon and 
rib, weighed and snap frozen in liquid nitrogen. Overall muscle cross-sectional area was determined by dividing 
the muscle mass by the product of optimum fiber length  (Lf which is equal to  Lo in diaphragm muscle strips) 
and 1.06 mg·mm–3, the density of mammalian muscle. All  Po values were normalized for muscle cross-sectional 
area and expressed as specific force  (sPo).
A 10 mm wide diaphragm strip was excised from the linear muscle fibers in the right costal region of the 
diaphragm and frozen in thawing isopentane for histology and immunohistochemistry. The remainder of the 
costal diaphragm muscle was snap frozen for biochemical analysis. Heart weight was also recorded. All samples 
were stored at -80 °C.
Serum Creatine Kinase (CK) Activity. Serum CK activity was determined using a commercially available 
assay kit (ab155901; Abcam), as per manufacturer’s instructions.
Histology and wheat germ agglutinin staining (WGA). Transverse 8 μm thick frozen sections were 
cut from diaphragm muscle strips. Hematoxylin and eosin (H&E; Sigma-Aldrich) staining was used for muscle 
morphometric  analysis97. Digital images of H&E stained muscle were captured at 200 × magnification (DM1000 
upright microscope, Leica). All histology image analysis was completed using Image-Pro Plus software (Media 
Cybernetics). Muscle fibre size is expressed as minimal ferret diameter to control for variation in the orientation 
of the muscle cross-section.
WGA is an effective tissue marker for  fibrosis67, due to the presence of WGA binding sites in the pericellular 
and interstitial matrices which in dystrophic muscles are enriched with collagen, proteoglycans, and glycosamino-
glycans (e.g. hyaluronan)64,66. Diaphragm cross-sections were fixed in 4% PFA and stained with WGA conjugated 
with Alexa Fluor 594 (Thermo Fisher Scientific; 1:50 dilution in PBS) for 15 min. Nuclei were counter-stained 
with DAPI. Two non-overlapping images for each cross-section were captured on an Olympus 1X71 Inverted 
Fluorescence Microscope with an XM10 camera. To determine the percentage area of fibrosis in the diaphragm 
cross-sections, planimetric analysis of the digital images was completed using Image-Pro Plus software (Media 
Cybernetics)14,98.
Immunohistochemistry. Immunohistochemistry for V0/V1 versican (anti-GAGβ; Millipore, AB1033) 
and versikine (anti-DPEAAE neo-epitope; Thermo Fisher Scientific, PA1-1748A) was performed as previously 
 described22,26. For analysis of V0/V1 versican and versikine immunoreactivity, four non-overlapping representa-
tive digital images were captured with a confocal microscope of each muscle cross-section at 600 × magnification 
(Olympus Fluoview FV10i). To determine the percentage of muscle cross-section immunoreactive for versican 
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To demonstrate that versican synthesis and remodelling are associated with inflammation and regenera-
tion in dystrophic diaphragm muscles, serial sections were used to co-localize versikine with desmin or CD68. 
Desmin is expressed in activated satellite cells and newly regenerated muscle  fibres55, whilst CD68 is expressed 
by infiltrating monocytes and macrophages in various models of muscle damage, includes dystrophic muscles 
from mdx mice and patients with  DMD56,57,99,100. Serial sections were used, because the anti-verskine, anti-CD68 
(Abcam; ab125212) and anti-desmin (Abcam; ab15200) antibodies were all raised in the same species (rabbit). 
Immunohistochemistry for desmin was performed as previously  described22,26, and for CD68 as described below. 
A secondary Alexa Fluor 594 goat anti-rabbit antibody (Thermo Fisher Scientific; A32740; diluted in 1:1,000) was 
used to detect versikine and a secondary Alexa Fluor 488 goat anti-rabbit antibody (Thermo Fisher Scientific; 
A11034; diluted in 1:1,000) was used to detect desmin or CD68. Nuclei were counterstained with DAPI. For the 
co-localization experiments, representative digital images of diaphragm muscle cross-sections were captured 
with a confocal microscope at 600 × magnification (Olympus; Fluoview FV10i). Co-localization was confirmed 
on the basis of tissue morphology, hence phase images were captured and overlaid with the corresponding 
fluorescent images.
To support the co-localisation of versikine with inflammatory cells, and macrophages in particular, diaphragm 
cross-sections were co-reacted with an anti-F4/80 antibody raised in rats (Abcam, ab6640; diluted 1:100) and 
the anti-versikine antibody or the anti-CD68 antibody for 1 h. Followed by incubation with a secondary Alexa 
Fluor 594 goat anti-rabbit secondary antibody (diluted in 1:1,000) and a secondary Alexa Fluor 488 goat anti-
rat secondary antibody (Thermo Fisher Scientific; A11006; diluted in 1:1,000). Nuclei were counterstained with 
DAPI. A negative control diaphragm cross-section stained with goat anti-rabbit and goat anti-rat secondary 
antibodies was also included. Representative sections were captured at 400 × magnification with a laser scanning 
confocal microscope (Nikon A1Rsi).
To quantify monocyte macrophage infiltration (Fig. 8), diaphragm muscles cross-sections were reacted with 
an anti-CD68 primary antibody (Abcam; ab125212; diluted in 1:500) for 1 h, followed by incubation with 
an anti-rabbit-HRP linked secondary antibody (Jackson Labs; #111035003; diluted 1:1,000)101. The 3-amino-
9-ethylcarbazole (AEC; Sigma Aldrich; AEC101) substrate chromogen was used to visualise CD68 positive cells 
which stained the cytoplasm brownish-red. Nuclei were counterstained with Mayer’s haematoxylin. Three digital 
images were captured of each diaphragm cross-section at 200 × magnification (DM1000 upright microscope, 
Leica). CD68 positive cells positive cells were manually counted and expressed as number of cells per  mm2 of 
muscle cross-section.
Immunohistochemistry for MyHC type I and IIa fibers was completed following the protocol described 
by Bloemberg and  Quadrilatero102, using anti-MyHC I (BA-F8; DSHB; lot: 11515–43ug/ml; diluted 1:20) and 
anti-MyHC IIa (SC-71; DSHB; lot: 81315–65ug/ml; diluted 1:50). Following a 1 to 2 h of incubation with the 
MyHC primary antibodies, sections were reacted with an Alexa Fluor 350 goat anti-mouse IgG2b (Thermo Fis-
cher Scientific; A21140; diluted 1:500) for MyHC1 and Alexa Fluor 488 goat anti-mouse IgG1 (Thermo Fischer 
Scientific; A21121; diluted 1:500) for MyHC IIa. To determine the number of MyHC type I or type IIa positive 
fibers per  mm2 of muscle cross-section, two images per cross-section were captured at 200 × magnification using 
a fluorescent light imager (Zoe; Bio-Rad). All image analysis was completed using Image-Pro Plus software 
(Media Cybernetics).
collagen content. A hydroxyproline assay was used to determine the total collagen content of dystrophic 
diaphragm  muscles68. Briefly, 10 mg of tissue was homogenized in 100 μl of PBS. Following the addition of 100 μl 
of 12 M HCl, samples were hydrolysed overnight at 105 ○C. To quantify collagen content, 20 μl of muscle or 
standards (serial dilutions of 0.1 mg/ml of hydroxyproline in 1 mM HCl) were added to a 96-well plate, dried 
at 60 ○C, and followed by the addition of 100 μl of 1.4% freshly prepared chloramine-T solution. After a 5 min 
incubation at room temperature, 100 μl of a 4-(dimethylamino) benzaldehyde (DMAB) was added to each well. 
Samples were the incubated for another 90 min at 60 ○C and then read at 550 nm on a spectrophotometer. 
Results are reported as μg of hydroxyproline per mg of wet weight tissue.
Real time quantitative PCR (qPCR). Diaphragm muscles were homogenized in TRIzol reagent (Thermo 
Fischer Scientific; 15,596,026) using a handheld homogeniser as previously  described14. Briefly, total cellular 
RNA was extracted and purified using a RNeasy Mini Kit (Qiagen). An iScript cDNA synthesis kit (Bio-Rad) 
was used to reverse transcribe 0.25 μg of total RNA. Quantitative RT-PCR was performed using IQ SYBR Green 
Super mix (Bio-Rad) and oligonucleotide primers for the genes of interest (Supplementary Table 1)98. cDNA 
concentrations were determined using Quant-iT OliGreen ssDNA reagent (Thermo Fisher Scientific), and Ct 
values were normalized to cDNA content.
Statistics
All data are presented as mean ± SEM with Gaussian distribution assumed. An independent sample t-test or a 
2-way General Linear Model (GLM) ANOVA, followed by Tukey’s post hoc analysis where appropriate, were 
performed as indicated. All statistical analyses were performed using Minitab statistical software v17 (Sydney, 
AUS), with p  < 0.05 being statistically significant.
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